Singapore: Dehaier Medical Systems, an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, has entered into a three-year strategic mutual cooperation agreement with HEYER Medical, an internationally recognized, German-based, company specializing in state-of-the-art inhalation and anesthesia equipment, oxygen concentrators, breathing therapy equipment and connecting equipment. Management of both parties hosted the signing ceremony at Dehaier's headquarters in Beijing on June 5, 2012. 

According to the agreement, Dehaier will continue to be one of the key distributors for HEYER's anesthesia machines and exclusive distributer of nebulizers in China. HEYER's anesthesia machines and inhalation equipment currently holds a large market share in China, and the company believes that there are a number of significant growth opportunities for HEYER's products throughout the country. As their distributor, Dehaier will continue promoting and marketing the products, using its solid professional sales experience and rich customer resource. During the period of a long and close working relationship between both parties, Heyer expressed its highly appreciation for Dehaier's medical and homecare business. As the mutual cooperation with Heyer indicated in the agreement, Dehaier will also provide medical products as well as technical services for Heyer in turn delivering quality, cost-effective products to the majority of countries that Heyer serves, predominantly the Asia, East Asia and Africa regions.

Dehaier's CEO, Mr Ping Chen stated, "We continue to build long-lasting relationships with many of the industry's most renowned medical manufacturers. I met with Mr Klaus Schickhaus, CEO, Heyer Medical in Beijing last year, and he also showed great interest in Dehaier's homecare market portfolio and is reviewing opportunities for potential joint cooperation. We are delighted to be working with Heyer, and feel this is a good opportunity for Dehaier to strengthen our international market expansion, enhance our brand awareness, improve our R&D capability, and eventually realize substantial growth in sales revenue for the benefit of our shareholders."